Picture loading failed.

Anti-APP therapeutic antibody (Pre-made Bapineuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Bapineuzumab (nicknamed "bapi")] is a humanized monoclonal antibody that acts on the nervous system and may have potential therapeutic value for the treatment of Alzheimer's disease nd possibly glaucoma. However, in 2012 it failed to produce significant cognitive improvements in patients in two major trials, despite lowering key biomarkers of AD, amyloid brain plaque and hyperphosphorylated tau protein in CSF.[

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-046-1mg 1mg 3090
GMP-Bios-ab-046-10mg 10mg 21890
GMP-Bios-ab-046-100mg 100mg 148000
GMP-Bios-ab-046-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-APP therapeutic antibody (Pre-made Bapineuzumab biosimilar,Whole mAb)
INN Name Bapineuzumab
TargetAPP
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI Structure4ojf:HL/4hix:HL
Year Proposed2005
Year Recommended2006
CompaniesJANSSEN Alzheimer Immunotherapy;Pfizer;Wyeth;Elan Corporation
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAlzheimer's disease
Development Techna